v. 26 – Q2 2023
| Market Executive Summary |
Process: Systematic end-to-end verification (“before being dispensed to patients e.g. at pharmacy level”) supplemented by risk-based verifications by wholesale distributors: “Medicines at higher risk of falsification (returns or medicines not being distributed directly by manufacturers or marketing authorisation holders or wholesalers distributing on their behalf)”
System: Central European Hub and National Medicines Verification Systems in every participating market (Note: Belgium/Luxembourg and Switzerland/Liechtenstein both share a multi-market repository) Safety Features: 4-data Element Unique Identifier plus mandatory anti-tamper device |
| Key Dates |
|